Selux Diagnostics

Fighting antimicrobial resistance with a Next-Generation Phenotyping (NGP) platform that enables personalized antibiotic therapies for patients.

[Selux Diagnostics @SeluxDX]

Grateful for the brilliant minds behind our rapid AST technology. Our Seluxors are working tirelessly to bring solutions to the fight against antimicrobial resistance (AMR).

[Selux Diagnostics @SeluxDX]

The Selux NGP System is a rapid phenotypic AST platform delivering results from positive blood culture and isolates in as little as 5.5 hours. Learn more about the power of Selux here: https://t.co/qAbQSAJuIi

[Selux Diagnostics @SeluxDX]

Selux had the pleasure of hosting Jack and Jill of America Boston Chapter intermediate group for a day of hands-on science experiments + learning in the lab. It was an honor to share our work with these future leaders, and we can’t wait to see what they'll accomplish.

[Selux Diagnostics @SeluxDX]

We're spreading the word, not superbugs. Selux is at the forefront of the fight against antimicrobial resistance (AMR). Learn how the Selux NGP System delivers rapid AST: https://t.co/cuLYh8ofMT

[Selux Diagnostics @SeluxDX]

Dr. Thomas Kirn’s presentation, "Does Speed Matter" shows that faster AST results on non-blood culture isolates lead to reduced hospital stays, lower costs, and higher odds of patients being discharged to home.

[Selux Diagnostics @SeluxDX]

This week is the WHO's World Antimicrobial Awareness Week. At Selux, it's our mission to preserve the lifesaving power of antibiotics for future generations. Check out how we're making an impact: https://t.co/LScK5olL7d

[Selux Diagnostics @SeluxDX]

Dr. Thomas Kirn, MD, Ph.D., says that speed matters when it comes to AST, both from a cost perspective and a clinical perspective. He highlights that shorter TTR on isolates lead to better patient outcomes, shorter hospital stays, and reduced costs. https://t.co/U60G1NbX2G

[Selux Diagnostics @SeluxDX]

With AMR on the rise, rapid AST is critical in combating the 'silent pandemic.' Dr. Thomas Kirn, MD, Ph.D., revealed that 63% of patients had an antibiotic change after receiving rapid AST results, leading to more effective treatments.https://t.co/4l2q942rdr

[Selux Diagnostics @SeluxDX]

Meet the team at Selux Diagnostics, pushing the boundaries of rapid AST technology to ensure patients receive faster, more precise treatment: https://t.co/tNXV7moUxT

[Selux Diagnostics @SeluxDX]

The AMR crisis is on the rise, with an estimate of 40M lives at risk by 2050. Though this is a shocking number, there is hope. "In a scenario where the world has better health care, 92 million cumulative deaths could be averted between 2025 and 2050." https://t.co/QD5FAOZcrq

[Selux Diagnostics @SeluxDX]

Outdated breakpoints can put a patient's life at risk. American Society for Microbiology advises, "...antimicrobial resistance within organisms evolve over time, and so too should clinical breakpoints." Source: https://t.co/85ODezJrkD

[Selux Diagnostics @SeluxDX]

Rapid AST results are essential for patient care and cost savings alike. Dr. Thomas Kirn highlights how faster results from non-blood culture isolates improve outcomes, reduce hospital stays, and cut costs. Check out the full presentation: https://t.co/FlN7x03wFg

[Selux Diagnostics @SeluxDX]

Over the next 25 years, an estimated 39 million people are expected to die from drug-resistant pathogens alone. The American Society of Microbiology advises that to help mitigate this health crisis, we need to continue the conversation about AMR.
Source: https://t.co/J7hMN3Dn6s

[Selux Diagnostics @SeluxDX]

ASM published an article highlighting data from a study projecting a 70% increase in deaths due to AMR from 2022 to 2050. The Selux NGP System, a rapid AST platform, is helping preserve the lifesaving power of antibiotics: https://t.co/qZc0qAiSNZ
https://t.co/xVQMBm8DdW

[Selux Diagnostics @SeluxDX]

The Selux Direct from Positive Blood Culture Separator received Breakthrough Designation from the U.S. FDA for sterile body fluids and positive blood culture. It is uniquely positioned to speed up time to result for infectious disease patients.

[Selux Diagnostics @SeluxDX]

As a single-platform technology, the Selux Next Generation Phenotyping (NGP) System helps boost lab efficiency by delivering quick results, ultimately leading to faster, better patient care.

More about our clearance here:
https://t.co/oyTwR29omI

[Selux Diagnostics @SeluxDX]

Highlighting the trailblazers behind the next generation of AST. Learn more about the Selux NGP System: https://t.co/vA0DaOxh78

[Selux Diagnostics @SeluxDX]

Only 30 to 60% of U.S. labs use updated breakpoints. Why is this a problem?
1. Clinicians are not able to make appropriate decisions for therapies based on the data they have
2. Patients are less likely to receive effective therapy

Source: https://t.co/7nWdHnodik

[Selux Diagnostics @SeluxDX]

The Selux NGP System represents a leap forward in speed. By not needing ID before initiating AST, we allow the lab flexibility to perform these processes in tandem, delivering results within the same shift. Learn more about the system here: https://t.co/zbtYDEe5Nc

[Selux Diagnostics @SeluxDX]

Dr. Vincent Streva, PhD, D(ABMM), emphasizes that in addition to improving the time to administration of effective antimicrobial therapy, rapid AST systems are "helpful for stewardship, for de-escalation..." Watch the whole presentation here: https://t.co/yxyoOeLr7s